search
Back to results

M-Suubi: A Multi-Level Integrated Intervention to Reduce the Impact of HIV Stigma

Primary Purpose

HIV/AIDS

Status
Recruiting
Phase
Not Applicable
Locations
Uganda
Study Type
Interventional
Intervention
Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE
Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE plus Group-based stigma reduction for educators (GED-HIVSR).
Bolstered Standard of Care (BSOC)
Sponsored by
Washington University School of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for HIV/AIDS focused on measuring AIDS PREVENTION, ADOLESCENT, ADHERENCE, AIDS/HIV PROBLEM

Eligibility Criteria

10 Years - 17 Years (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • HIV-positive adolescents confirmed by medical report
  • Prescribed antiretroviral therapy
  • Enrolled in primary and secondary schools in a boarding section
  • Caregivers of ALHIV who agree to participate in the study
  • Teachers, school nurses, and administrators in the target schools who agree to participate in the study

Exclusion Criteria:

- A significant cognitive impairment that interferes with the participant's understanding of the informed consent process, or inability/unwillingness to commit to completing the study

Sites / Locations

  • International Center for Child Health and Development Field OfficeRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Other

Arm Label

Treatment Arm 1

Treatment Arm 2

Control Arm

Arm Description

Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE

Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE plus Group-based stigma reduction for educators (GED-HIVSR)

Bolstered Standard of Care (BSOC)

Outcomes

Primary Outcome Measures

Change HIV viral suppression
Change in viral suppression will be assessed using viral load (VL) data collected from health clinic records. VL will be dichotomized between undetectable /suppression (VL< 40 copies/ml) and detectable/failed viral suppression (VL > =40 copies/ml) levels at each assessment time.

Secondary Outcome Measures

Change in Adherence and retention in care
Change in adolescent Self reported medication adherence. This will be measured using the Adherence and retention in care questionnaire focusing on the pharmacy refills, pill counts and missed appointments at each assessment time.
HIV Stigma Measure for Children
HIV-associated stigma for children will be measured using the HIV Stigma Measure. We will measure the mean score over time. The total score range between 40- 160 with a high score indicating higher levels of perceived HIV-associated stigma.
The Shame Questionnaire for Children
Shame related to living with HIV will be measured using the Shame Questionnaire. We will measure the mean score over time. The total score range between 0 and 16 with a higher score indicating higher levels of HIV-associated shame.

Full Information

First Posted
December 21, 2021
Last Updated
July 26, 2023
Sponsor
Washington University School of Medicine
Collaborators
National Institute of Mental Health (NIMH)
search

1. Study Identification

Unique Protocol Identification Number
NCT05307250
Brief Title
M-Suubi: A Multi-Level Integrated Intervention to Reduce the Impact of HIV Stigma
Official Title
M-Suubi: A Multi-Level Integrated Intervention to Reduce the Impact of HIV Stigma on HIV Treatment Outcomes Among Adolescents Living With HIV in Uganda
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 15, 2022 (Actual)
Primary Completion Date
July 31, 2026 (Anticipated)
Study Completion Date
July 31, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Washington University School of Medicine
Collaborators
National Institute of Mental Health (NIMH)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
M-Suubi, a three arm cluster randomized study will examine the effects and cost-effectiveness of a multi-level intervention on HIV viral suppression among 840 adolescents living with HIV (ALHIV) enrolled in 42 secondary schools with a boarding section. The investigators will test the effects of a group-based HIV stigma reduction intervention for educators (GED-HIVSR), over and above the effects of multiple family groups with HIV stigma reduction combined with family economic empowerment (MFG-HIVSR plus FEE), relative to Bolstered Standard of Care (BSOC). ALHIV will be randomized at the school level to one of three study arms
Detailed Description
HIV stigma remains a formidable barrier to HIV treatment adherence among adolescents in Uganda, contributing to low rates of medication adherence and viral suppression (less than 50%) and high attrition from HIV treatment services. ALHIV experience HIV stigma (internalized, anticipated and enacted) in various settings, including families and schools, the most important developmental contexts that should otherwise be supportive of their development and wellbeing. One of the unique features about education in Uganda and other countries in Sub-Saharan Africa is the high proportion (over 60%) of school-going adolescents enrolled in boarding secondary schools - which represent a form of parental opt-in institutionalized care. ALHIV in schools are more disadvantaged and have lower levels of HIV treatment adherence due to high levels of HIV stigma within schools, rigid school structures and routines, lack of adherence support and food insecurity. Within families, HIV stigma is perpetuated in various forms including discrimination and violence, often due to unfounded fears of infection-hence undermining the quality of family relations and supports for ALHIV. Building on our research and current evidence on HIV stigma reduction, the investigators propose a multi-level three-arm cluster randomized study (M-Suubi) with the following specific aims: Aim 1: Examine the impact of M-Suubi on HIV viral suppression (primary outcome); and adherence to HIV treatment (keeping appointments, pharmacy refills, pill counts), and retention in care (secondary outcome); Aim 2: Examine the effect of M-Suubi on HIV stigma (internalized, anticipated and enacted), with secondary analyses to explore hypothesized mechanisms of change (e.g. depression) and intervention mediation; Aim 3: Assess the cost and cost-effectiveness of each intervention condition; and Aim 4: Qualitatively examine: a) participants' experiences with HIV stigma, HIV treatment adherence, and the intervention; and 2) educators' attitudes towards ALHIV, experiences with GED-HIVSR, and program/policy implementation post-training. The study will enroll 840 ALHIV recruited from 42 schools located within the greater Masaka region, heavily affected by HIV (prevalence 12% vs 7.3% national average). M-Suubi will be provided for 20 months, with assessments at baseline, 12, 24 and 36 months. Findings may inform combination intervention efforts to optimize HIV treatment outcomes and engagements in care among ALHIV.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV/AIDS
Keywords
AIDS PREVENTION, ADOLESCENT, ADHERENCE, AIDS/HIV PROBLEM

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
840 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Treatment Arm 1
Arm Type
Experimental
Arm Description
Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE
Arm Title
Treatment Arm 2
Arm Type
Experimental
Arm Description
Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE plus Group-based stigma reduction for educators (GED-HIVSR)
Arm Title
Control Arm
Arm Type
Other
Arm Description
Bolstered Standard of Care (BSOC)
Intervention Type
Behavioral
Intervention Name(s)
Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE
Intervention Description
In addition to the BSOC, ALHIV and their caregivers will participate in a family strengthening intervention plus a family economic empowerment intervention. MFG is an evidence-based family-centered, group-delivered, evidence-informed, strength-based 10-session (weekly) intervention for children whose families struggle with poverty. Six additional sessions covering HIV stigma stigma-related issues will be added. ALHIV will receive a YDA with a 1:1 matched savings program at a financial institution accredited by the Bank of Uganda. Each YDA will be opened in the name of the adolescent, with their primary caregiver as a co-signer, until the adolescent turns 18 years. The account will then be matched with money from the program on 1:1 rate.
Intervention Type
Behavioral
Intervention Name(s)
Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE plus Group-based stigma reduction for educators (GED-HIVSR).
Intervention Description
In addition to BSOC and MFG-HIVSR+FEE, ALHIV in this arm will receive the school-level HIV stigma reduction intervention targeting teachers, school nurses, matrons, and administrators (headteachers, director of studies) in their schools. GED-HIVSR seeks to impart educators in the intervention schools with HIV related knowledge, provide a safe space for educators to explore their personal values and bias that may promote or hinder their role of supportive individuals and systems for ALHIV, and empower them with knowledge and skills to act as change agents within their schools.
Intervention Type
Other
Intervention Name(s)
Bolstered Standard of Care (BSOC)
Intervention Description
All participants (in control and treatment arms) will receive medical and psychosocial support as part of the BSOC. 1) Medical SOC: All public clinics, including our study sites, follow procedures for pediatric ART initiation and monitoring, as outlined in the National Department of Health Guidelines for pediatric HIV care in Uganda. Specifically, immediately after initiation, or if clinically unstable, ALHIV are seen more frequently (weekly to monthly). Laboratory data (VL and CD4 counts) are collected every six months until the patient is stabilized and then annually, using the National Health Laboratory Service standardized protocol. A
Primary Outcome Measure Information:
Title
Change HIV viral suppression
Description
Change in viral suppression will be assessed using viral load (VL) data collected from health clinic records. VL will be dichotomized between undetectable /suppression (VL< 40 copies/ml) and detectable/failed viral suppression (VL > =40 copies/ml) levels at each assessment time.
Time Frame
Baseline 12, 24 and 36 month follow-up
Secondary Outcome Measure Information:
Title
Change in Adherence and retention in care
Description
Change in adolescent Self reported medication adherence. This will be measured using the Adherence and retention in care questionnaire focusing on the pharmacy refills, pill counts and missed appointments at each assessment time.
Time Frame
Baseline 12, 24 and 36 month follow-up
Title
HIV Stigma Measure for Children
Description
HIV-associated stigma for children will be measured using the HIV Stigma Measure. We will measure the mean score over time. The total score range between 40- 160 with a high score indicating higher levels of perceived HIV-associated stigma.
Time Frame
Baseline 12, 24 and 36 month follow-up
Title
The Shame Questionnaire for Children
Description
Shame related to living with HIV will be measured using the Shame Questionnaire. We will measure the mean score over time. The total score range between 0 and 16 with a higher score indicating higher levels of HIV-associated shame.
Time Frame
Baseline 12, 24 and 36 month follow-up
Other Pre-specified Outcome Measures:
Title
Child Depression Inventory (CDI)
Description
Depressive Symptoms will be measured using the Child Depression Inventory (CDI) scale. We will measure the mean score on the CDI scale over time. The total score range between 0 and 28 with a high score indicating higher levels of depressive symptoms.
Time Frame
Baseline 12, 24 and 36 month follow-up
Title
Post-Traumatic Stress Disorder (PTSD)
Description
Post-Traumatic Stress Disorder (PTSD) will be measured using the Child PTSD Reaction Scale. We will measure the mean score on the Child PTSD Reaction Scale over time. The total score range between 0 and 120, with a high score indicating higher levels of PTSD.
Time Frame
Baseline 12, 24 and 36 month follow-up
Title
Tennessee Self-Concept Scale (TSCS)
Description
Self concept will be measured using the Tennessee Self-Concept Scale (TSCS). We will measure the mean score on the TSCS over time. The total score range between 20 and 100 with a high score indicating higher levels of self-concept.
Time Frame
Baseline 12, 24 and 36 month follow-up
Title
Beck Hopelessness Scale (BHS)
Description
Hopelessness will be measured using the Beck Hopelessness Scale (BHS). We will measure the mean score on the BHS over time. The total score range between 0 and 20 with a high score indicating higher levels of hopelessness.
Time Frame
Baseline 12, 24 and 36 month follow-up
Title
HIV Adherence Self-Efficacy Scale
Description
Self reported medication adherence will be measured by the number of times a child missed taking medication in the past 30 days, and number of days took medication the way they were supposed to. HIV Adherence Self-Efficacy Scale (HIV-ASES)
Time Frame
Baseline 12, 24 and 36 month follow-up
Title
Family relations
Description
Change in family relations will be measured by Family Environment Scale
Time Frame
Baseline 12, 24 and 36 month follow-up
Title
Social Support Behaviors Scale
Description
Social support from family members and friends will be measured using the Social Support Behaviors Scale (SSBS). We will measure the mean score on the SSBS over time. The total score ranges between 45-225, with higher score indicating higher levels of social support.
Time Frame
Baseline 12, 24 and 36 month follow-up
Title
Rosenberg Self-Esteem Scale
Description
Self- Esteem will be measured using the Rosenberg Self-Esteem Scale. The total score range 0-30 where a score less than 15 may indicate a problematic low self esteem.
Time Frame
Baseline 12, 24 and 36 month follow-up
Title
Savings Deposits
Description
Change in savings will be measured by Bank statements and financial diaries. Minimum savings will be 0.
Time Frame
Baseline 12, 24 and 36 month follow-up
Title
Financial Literacy
Description
Change in Financial Literacy knowledge
Time Frame
Baseline 12, 24 and 36 month follow-up
Title
Caregiver mental health
Description
Hopkins Symptom Checklists will be used to measure symptoms of anxiety and depression. We will measure the mean score of the Hopkins Symptoms Checklists over time. High score indicates severe levels of anxiety and depression.
Time Frame
Baseline 12, 24 and 36 month follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: HIV-positive adolescents confirmed by medical report Prescribed antiretroviral therapy Enrolled in primary and secondary schools in a boarding section Caregivers of ALHIV who agree to participate in the study Teachers, school nurses, and administrators in the target schools who agree to participate in the study Exclusion Criteria: - A significant cognitive impairment that interferes with the participant's understanding of the informed consent process, or inability/unwillingness to commit to completing the study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Fred M Ssewamala, PhD
Phone
3149358521
Email
fms1@wustl.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Ozge Sensoy Bahar, PhD
Phone
3149359403
Email
ozge.sensoybahar@wustl.edu
Facility Information:
Facility Name
International Center for Child Health and Development Field Office
City
Masaka
Country
Uganda
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Flavia Namuwonge, BA
Phone
+256 793888706
Email
flavia.namuwonge9@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Once all of the data has been de-identified, cleaned, and validated, and main findings have been published, the Investigators expect to share data with the scientific community. The research team will make datasets available to any individual who makes a direct request to the PI and indicates the data will be used for the purposes of research (per Code of Federal Regulations Title 45 Part 46: "Research is defined as a systematic investigation, including research development, testing and evaluation, designed to develop or contribute to generalizable knowledge."). In sharing participant data, the team will follow Washington University in St. Louis' Office of Sponsored Projects' data sharing agreement.
Citations:
PubMed Identifier
36197706
Citation
Mutumba M, Ssewamala F, Namirembe R, Sensoy Bahar O, Nabunya P, Neilands T, Tozan Y, Namuwonge F, Nattabi J, Acayo Laker P, Mukasa B, Mwebembezi A. A Multilevel Integrated Intervention to Reduce the Impact of HIV Stigma on HIV Treatment Outcomes Among Adolescents Living With HIV in Uganda: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2022 Oct 5;11(10):e40101. doi: 10.2196/40101.
Results Reference
derived

Learn more about this trial

M-Suubi: A Multi-Level Integrated Intervention to Reduce the Impact of HIV Stigma

We'll reach out to this number within 24 hrs